Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leave a little room for ChrgD+ and Turbo CBD would ya?
http://fortune.com/2019/03/27/walgreens-selling-cannabis-cbd-sprays-patches-stores/
That's right canceled for non-performance, I think.
Growpacker deal was announced in April 2018. California cannabis company remains a mystery.
https://www.lexariabioscience.com/news/lexaria-enters-definitive-license-agreement-with-california-cannabis-beverage-manufacturer/
I see there's a link on https://chrgd.life/ where you can enter the last 5 digits of your lot number or 19094 and get a complete analysis of the product. This is a great selling point as it puts us above many others with products of dubious analysis.
That's great ChrgD+ finally!
Now if they'd only come out with the powder with THC or a combination THC and CBD. Should have various flavors like 1906 Chocolates: Love, Go, Chill, Midnight and Bliss
"If you can't wait that long you could sell your shares and put your money in a company that is a better bet. Good luck finding one."
ANY GOLD STOCK!
Only God and Chris know WTF they're doing!
WTF is a soft launch? We're going to sell this stuff, but shhhhhh don't tell anyone, it's a secret.
Where's the ChrgD+ with THC?
You won't hear any info regarding nicotine research and development from Altria until such time as they have a product ready for market testing.
My thoughts exactly.
If you look on the countertop beside Chris Bunka you will see a box of ChrgD+, this is the CBD drink powder that they have been threatening for 8 months, to launch in the US.
When?
It’s a pouch so it wouldn’t be ingestable, you probably suck on the pouch until the nicotine is absorbed through the oral membranes. Also they’re flavoured to hide the gross taste of the nicotine, not at all in the same category as DehydraTECH.
Hill Street to acquire OneLeaf Cannabis for $16M
2019-05-28 10:49 ET - News Release
Mr. Terry Donnelly reports
HILL STREET ANNOUNCES ACQUISITION OF ONELEAF CANNABIS
Hill Street Beverage Company Inc. has signed a binding Letter of Intent to acquire OneLeaf Holding Corp., the parent company of OneLeaf Cannabis Corp., an "evidence package" stage applicant to become a licensed cannabis cultivator and processor, in an all share transaction. The Company also announces a proposed non-brokered private placement of units for gross proceeds of up to $5 million.
"Transaction Positions Hill Street to become a Leading Producer of Infused Beverages"
Both Hill Street and OneLeaf believe that cannabis beverages will expand consumption of cannabis beyond just the consumer base willing to smoke or vape products. By combining Hill Street's award-winning alcohol-free beverages with OneLeaf's access to an award-winning and unique catalogue of cannabis genetics, the combined company will have the ability to become a leader in the infused beverages market, in addition to offering differentiated traditional cannabis products.
"The OneLeaf team has built a world class, 48,200 square foot facility, built to EU GMP standards, that will house growing, extraction, and infusion. It will house the infusion, bottling, and canning of our beverages under one roof. Their catalogue of over 700 distinct cannabis cultivars, which have been collected and cultivated by the founders, includes a collection of Cannabis Cup award-winning cultivars and a diverse selection of landrace varietals. We anticipate that OneLeaf's elite genetics, which include many cultivars not legally available anywhere else, will pair perfectly with our beverages to provide unique attributes and experiences for our consumers," said Terry Donnelly, Hill Street's Chairman and CEO. "We believe the integration of OneLeaf and Hill Street will make for a powerful force in the market, and positions Hill Street to become a leading producer of infused beverages and other cannabis products."
"Hill Street's beverages have already set themselves apart on the world stage," said Trevor Green, CEO of OneLeaf. "No other alcohol-free beer and wine producer has won as many major world championship competitions as Hill Street. With a complete portfolio of beverages ready for infusion, plus their demonstrated expertise in private label and branded beverages, we believe the OneLeaf facility will become a landmark in the industry, and the source of the finest cannabis infused beverages and other cannabis products in the market. With our world class cultivation and extraction capabilities, we will be able to produce unique cannabis cultivars to match both beverage and cannabis consumption occasions and experiences, whether they are adult format, nutraceutical, sport-recovery, wellness, or even prescription drug products."
Cannabis beverages are the fastest growing segment of the market in US states where they are legal, according to Headset/Nielsen, growing at up to 61% in the past year. Each of Hill Street and OneLeaf believe there is a significant opportunity to grow their brands, as well as provide co-packing services to many companies wishing to enter the cannabis beverage market but who do not wish to operate their own packaging and production facilities. This includes major multinational beverage companies, international cannabis companies looking to enter the highly regulated Canadian market, and licensed producers looking to produce beverages using their own cannabis extracts.
The parties believe beverage-format products can also be a new, differentiated delivery system for cannabis-derived precision medicines and therapies, allowing consumers and patients the ability to consume cannabis-derived products in public and social settings. The addition of Hill Street's demonstrated beverage expertise will help differentiate OneLeaf's existing product roadmap, which includes traditional cannabis products such as dried flower products, oils, edibles, and extracts.
Operations to Be Housed at the OneLeaf Facility
Hill Street anticipates that the entire OneLeaf team, including regulatory lawyers, a plant geneticist and biochemist, and experienced cultivation, extraction and quality assurance personnel, will join the Hill Street organization. Hill Street's production lines will be installed at OneLeaf's 48,200 square foot facility which is strategically located near the Global Transportation Hub in Regina, Saskatchewan, a tax advantageous location providing easy access to both North American and foreign markets.
The beverage production lines will have a projected output capacity capable of producing over 300,000 cases of infused wine and beer with expansion to be added as additional planned facilities become licensed under Health Canada. OneLeaf has output capacity in its existing and planned flowering rooms for 1800kgs of cannabis annually, plus up to 6.5 acres available for expansion on surrounding lands including outdoor growing capabilities.
Terms of the Acquisition
Pursuant to a Letter of Intent, dated May 27, 2019, Hill Street will acquire all of the issued and outstanding shares of OneLeaf for a purchase price of $16,000,000 to be paid and satisfied as follows:
$8 million in common shares in the capital of Hill Street ("Hill Street Common Shares") on the closing date at a price per share of $0.23. The vendors have agreed to escrow 50% of the shares issued on closing for a period of four months from the date of closing.
$8 million in Hill Street Common Shares, in three quarterly instalments over the eighteen months following the closing date, at a price per share equal to $0.43 per share or the volume weighted average price ten days prior to issuance, with a price maximum of $0.66, $0.75 and $0.85 per share for each installment respectively.
26,693,630 warrants purchase Hill Street Common Shares, which will be issued on closing, with each warrant entitling the holder thereof to acquire one Hill Street Common Share at a price per share equal to $0.66, for a period of five years from the date of closing. The warrants shall be subject to vesting conditions related to OneLeaf achieving certain performance-based milestones following closing, including minimum cultivation targets, revenue thresholds, receipt of a federal medical sales license, and the successful completion of an EU-GMP audit of the OneLeaf facility.
Hill Street will also assume up to $5.5 million in debt related to the construction of the OneLeaf facility.
The transaction is an "arm's length transaction", and is subject to the parties entering into a definitive share purchase agreement, customary due diligence, and regulatory approvals, including Health Canada and the TSX Venture Exchange. It is slated to close upon the issuance of a cultivation and standard processing license to OneLeaf by Health Canada, which is anticipated to occur within the next four months. The parties do not anticipate the closing of the acquisition will create a new control person in the Company. No finders fees are payable in connection with the transaction.
Proposed Non-Brokered Financing
In addition to the acquisition of OneLeaf, Hill Street announces a proposed non-brokered private placement of units ("Units") for aggregate gross proceeds of up to $5 Million, at a price of $0.20 per Unit. Each Unit will be comprised of one (1) Hill Street Common Share and one-half of one (1/2) warrant (each whole warrant a "Warrant"), with each Warrant entitling the holder thereof to acquire one (1) Hill Street Common Share at a price of $0.40 per share for a period of two (2) years from the date of Closing. The private placement is slated to close in tranches, with the first tranche to close on or before June 15, 2019, and is subject to the approval of the TSX Venture Exchange. The proceeds of the financing will be used to fund day to day operations, and general working capital purposes.
About OneLeaf Cannabis Corp.
OneLeaf Cannabis Corp. is a privately-owned craft-inspired cannabis cultivation and processing company based in Regina, Saskatchewan. OneLeaf has constructed a 48,200 square foot facility purpose built to EU GMP standards that incorporates vertical farming, LED lighting and advanced HVAC and automation systems. Phase 1 of OneLeaf's facility, which is substantially complete and in preparation to complete its evidence package, is comprised of approximately 17,000 square feet. Upon licensing, OneLeaf will own a vast collection of unique cannabis genetics with differentiated attributes and properties, and intend to research and develop consumer, medical, and therapeutic products based on the diverse cannabinoid content found within its collection. OneLeaf's cultivation team has won multiple Cannabis Cups and is focused on producing exceptional quality product for the premium consumer and medical marketplaces.
About Hill Street Beverage Company Inc.
Hill Street Beverage Company is the world's most award-winning company exclusively focused on alcohol-free beer, wine, and adult-format beverages. Hill Street's great-tasting products include Hill Street Craft Brewed Lager, Designated Draft alcohol-free beer, Vin(Zero) wines, and Vintense wines, and have won numerous medals and accolades including three Gold, two Silver, and two Bronze Medals at the U.S. Open Beer Championships, the Retail Council of Canada's Grand Prix award, and a prestigious Double Gold Medal at the San Francisco International Wine Challenge. Hill Street will also produce and sell cannabis-infused adult beverages as soon as the sale of cannabis edibles becomes legal in Canada, expected to occur by October 17, 2019. Check out Hill Street's award-winning line-up and order product to be delivered straight to your home at www.hillstreetbeverages.com.
We seek Safe Harbor.
News Release
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients
Canada NewsWire
OTTAWA, Ontario, May 28, 2019
OTTAWA, Ontario, May 28, 2019 /CNW/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development. Because people are living longer around the world, the global chronic pain treatment market is expected to reach $105.9 billion by 2024.
"Bringing our chronic-neuropathic pain formulations into preclinical animal studies is an important milestone in the development of these patent-pending, time-released formulations," said Dr. Andrea Small-Howard, Chief Science Officer and Director of GBS Global. "We are very fortunate to be working with Dr. Ellis on this important project because of his unique experience in developing novel animal models for studying pain therapies and his track record of publications on the efficacy of cannabinoid-based therapies. Dr. Ellis and his team have also been performing preclinical animal testing on the safety and efficacy of GBS Global's Parkinson's disease therapies, so we know that they are great collaborators."
Providing sustained relief from chronic-neuropathic pain would bring quality of life to tens of millions of patients throughout the world who suffer from conditions such as fibromyalgia, spine compression-related neuropathy, post-herpetic neuropathy, diabetic peripheral neuropathy; as well as, cancer-related and HIV/AIDS-related neuropathies.
"The disease models that have been and are being developed at the NRC are designed to provide novel platforms for the initial screening of potential therapeutics," said Dr. Ellis. "We have shown that these animal models can be used to test the effectiveness of cannabinoids, and we are looking forward to evaluating how the results compare to GBS Global's time-released formulations."
GBS Global's orally-administrated, time-released, chronic-neuropathic pain formulations use nanotechnology to encapsulate the cannabis-based ingredients within a polymeric matrix to: 1) avoid digestion of the active ingredients; 2) target their absorption; 3) prolong blood circulation; and 4) provide a slow and steady release of active molecules. This medicine could be a game changer for people who suffer from chronic-neuropathic pain.
About GBS Global Biopharma, Inc.
GBS Global Biopharma, Inc, is a cannabinoid medicine development company located in Ottawa, Canada. Cannabinoid medicine is new science featuring 480+ active ingredients modulating GPCR and Ionotropic receptors involved in many disease conditions and notably those with no treatment or related to opioid addiction. GBS Global proprietary HTS/in Silico platform generates APIs for medical cannabis, nutraceutical supplement and prescription drug markets. The company currently has Rx programs in late pre-clinical and OTC programs at the formulation stage. GBS is working with nanotech time-released and rapid dissolve technology for effective oral delivery of their formulations. To learn more, go to: https://gbsglobalbiopharma.com.
About the National Research Council Canada
Recognized globally for research and innovation, Canada's NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. As home to Canada's national research laboratories, the NRC undertakes and promotes research and development in support of the Canadian science and technology community, in matters affecting the design, manufacture, performance, use and safety of its science and technology.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: https://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Hill Street Beverages Halted.
Amazing results from @lexariacorp Effects in 2min, 5x more effective in delivering CBD / THC into the bloodstream. Means 10mg dose feels like 50mg. https://t.co/Ku0UYcuAYQ
— Hill Incorporated (formerly Hill Street BevCo) (@HillStreetBevCo) May 15, 2019
https://chrgdlife.com/ now says Almost Ready Coming in June
This stuff is crap. Red Bull with hemp oil. It hasn't even been infused with CBD or THC just hemp oil. Diabetes in a can!
Prior to today's warrant news, LXX had 3 million warrants O/S at an average of $1.66.
I emailed Alex Blanchard and that is his response, also said to expect lots of news in coming months.
ChrgD+
"ChrgD is packaged and off to our distributors and you will start seeing it on shelves in Washington, Oregon and Texas in the next few weeks. We will issue a press release about availability and the launch of the e-commerce site at this time. We were originally looking at launching the product in California but health departments in several cities in the state started pulling CBD infused product off shelves in January. There is legislation at both the state and federal level that will deal with this situation but it caused us to delay the launch slightly and focus initially on states where the product is permitted to be sold."
What's Next for Infused Products
https://mjbizmagazine.com/digital-issues/2019-05-MayJun/42/
I don't blame you for losing confidence. It doesn't help that ChargD+, their industry disrupting, game-changing product was supposed to launch in November but flamed out, and then the new launch was changed to late March early April and that didn't happen either. Bad weather over the Cape I suppose. Certainly disappointing and a confidence disruptor for sure!
A real Bunka bust!
Good volume on BEER:C again today, 1.4 million so far. Strong resistance at .22-.23 though.
Then there's Sproutly:
2019-04-30 11:53 ET - News Release
Mr. Keith Dolo reports
SPROUTLY ANNOUNCES JOINT VENTURE WITH MOOSEHEAD BREWERIES TO LAUNCH CANNABIS-INFUSED BEVERAGES IN CANADA
Sproutly Canada Inc. and OCC Holdings Ltd., an affiliate of Moosehead Breweries Ltd., have entered into a definitive agreement to form an exclusive joint venture (JV) to develop, produce and market non-alcoholic cannabis-infused beverages in Canada, using Sproutly's proprietary, naturally produced water-soluble cannabinoids, known as Infuz2O. Both companies will bring their respective strengths to the joint venture to develop a line of great tasting cannabis beverages featuring a rapid onset and offset effect, unique to the category. Sproutly will host a conference call with Keith Dolo, chief executive officer of Sproutly Canada, and Matthew Oland, Moosehead executive and incoming CEO of the JV, at 9:30 a.m. ET on May 1, 2019.
Joint venture highlights:
Partnership with the oldest and largest independent brewery in Canada:
Moosehead has over 152 years of brewing experience through six generations of family ownership.
Moosehead has more than 140 million cans/bottles of beer sold annually throughout Canada, the United States and in 15 other countries around the world.
The Oland family has proven ability in building, marketing and selling industry-leading beers, such as Moosehead Lager, Moosehead Radler, Alpine and Hop City Barking Squirrel.
Competitive advantage driven by Infuz2O:
The JV beverages can deliver the cannabis effect as early as five minutes and last up to 90 minutes, providing an edible cannabis experience similar to traditional flower cannabis without the need to inhale smoke.
It has the ability to address the industry challenges of overconsumption of oil-based edibles and beverages.
It has the capability to produce a clear cannabis beverage that is much easier and faster to formulate than its competitors who will be using emulsifiers, encapsulation or chemical modification techniques.
It has the ability to deliver functional beverages that address a need state by producing cannabis strain specific experiences.
Natural Infuz2O process allows for a premium consumption experience and taste profile.
JV well positioned to enter cannabis beverages upon legalization:
Moosehead's beverage experience and research and development formulation capabilities will ensure that the cannabis beverages produced will be premium in quality and have a great taste profile.
Moosehead's established operational infrastructure will allow the joint venture to fast-track its go-to-market strategy.
Sproutly's cultivation facility and processing licence will advance the formulation work that has been completed to date, as well as production scale-up.
Alignment of interests:
The joint venture is structured as a 50/50 equity ownership.
Matthew Oland, one of Moosehead's senior executives and Oland family member, will lead the joint venture as chief executive officer.
Moosehead will provide infrastructure support, such as research and development, operations, procurement, finance, and distribution.
Sproutly will provide proprietary custom compositions using Infuz2O for cannabis beverages in Canada.
JV will have exclusive rights to utilize Infuz2O for cannabis beverages for a period of five years with a possible two-year extension.
The JV will have the ability to enter the European market once recreational cannabis use is legalized.
"With the anticipated legalization of edibles in Canada later this year, Moosehead has made the strategic decision to enter the cannabis beverage market. As one of the oldest brands in Canada and a leader in the beer category, we believe we are uniquely positioned to be a leader in the cannabis beverage category," said Andrew Oland, chief executive officer of Moosehead. "As a 152-year-old company spanning six generations, we are very selective about new business opportunities. After a significant amount of due diligence on Sproutly's APP technology and Infuz2O water-soluble cannabinoids versus other competitive technologies, we are excited to announce this joint venture. With their advanced technology and our long-standing product development experience, we expect to bring to Canadian consumers cannabis beverages that address the major issues currently limiting appeal of this category in other markets, a beverage that 1) actually tastes good and 2) provides an immediate and controllable cannabis experience lasting up to 90 minutes."
"Moosehead is a truly iconic brand and we are very excited to partner with a company that possesses such deep-rooted Canadian heritage and over 152 years of history in the beer industry. Partnering with a company of this caliber is a strong validation of APP technology and Infuz2O," commented Keith Dolo, CEO and a director of Sproutly. "This partnership with Moosehead marks an important milestone in Sproutly's mission of delivering a safe and consistent whole plant experience from cannabis, with a lead position in the beverage market. We have developed a relationship with Moosehead built on trust and our shared vision of creating safe, responsible and high-quality cannabis beverages and we look forward to making this a reality for Canadian consumers," added Mr. Dolo.
"After careful analysis of the cannabis industry and the cannabis beverage opportunity in Canada, we believe that Moosehead and Sproutly together are well positioned to become a significant player in the category," said Matthew Oland, incoming CEO of the joint venture. "The JV's ability to leverage Moosehead's rich history of building adult beverage brands and its established R&D and operational infrastructure will enable the JV to bring great tasting cannabis beverages to Canadian consumers. The Infuz2O technology delivers a natural cannabis beverage experience, with an onset and offset time similar to traditional flower cannabis, without the need for chemical modification. We believe this will be a game changer for the sector."
Terms of the joint venture
The joint venture will be structured as a standalone company with its own board of directors and management team. Sproutly and Moosehead will each hold a 50-per-cent interest in the JV and have the right to nominate three directors. Moosehead shall appoint the CEO and Sproutly shall appoint the chairperson of the board of directors of the JV.
Sproutly will provide Infuz2O exclusively to the joint venture in canada for the purpose of producing cannabis beverages (excluding hemp) for a period of five years, such exclusivity period being subject to a potential extension based on the joint venture reaching certain revenue targets.
The formation of the joint venture is subject to the satisfaction of certain conditions, including the execution and delivery of various transaction agreements, governance documents and supply agreements. The parties expect to form the joint venture on or before May 31, 2019.
Financial adviser
No idea, but I understand they've been negotiating a supply agreement with LPs for the oil to infuse into their beverages.
Volume spiking on our licensee Hill Street Beverages (BEER) this am.
Probably little or no compensation other than their expenses would be covered. If any compensation was material it would have to be disclosed.
These guys are in it for the love of science.
Did you just wake up?
The patent is still pending, I believe. It's HARD to wait. LOL
Kelowna, British Columbia – November 9, 2017 – Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has filed a new patent application with the US Patent and Trademark Office (“USPTO”) utilizing the Lexaria DehydraTECHTM technology for delivery of phosphodiesterase type 5 (PDE5) inhibitors – trade names of existing well-known products include ViagraTM (sildenafil) and CialisTM (tadalafil).
In its new patent application, Lexaria has named the PDE5 inhibitors from the group consisting of avanafil, lodenafil, mirodenafil, sildenafil (or analogs thereof, for example, actetildenafil, hydroxyacetildenafil, or dimethylsildenafil), tadalafil, vardenafil, udenafil, acetildenafil, and thiomethisosildenafil. In addition, under the new patent application each of these named molecules may be combined with a cannabinoid such as cannabidiol (“CBD”), where the cannabinoid delivered in concert may provide complementary vasodilatory activity beneficial together with the PDE5 inhibitor.
A common complaint of existing PDE5 delivery is the slow-acting nature of the substances. Building on existing successful research with cannabinoid delivery, Lexaria believes its patented DehyraTECHTM technology will allow for faster acting treatments in many cases utilizing lower dosage quantities.
As is true with Lexaria’s other patents and patent applications, the new PDE5 patent application is for the improved and more rapid delivery of the named molecules and is meant to be complimentary to existing or newly planned consumer products with a view to attracting prospective licensees or partners interested in utilizing Lexaria’s technology in next generation commercial products.
Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.
Old News Here's the pertinent news release that has probably piqued the interest of all these renowned neuroscientists.
Kelowna, British Columbia – June 29, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office (“USPTO”) for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer’s, Huntington’s, Parkinson’s, neuropathic pain and more.
In recent laboratory testing, Lexaria’s breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECHTM than concentration-matched controls lacking DehydraTECHTM enhancements. The study provided evidence of surprising effectiveness in crossing the blood-brain barrier (“BBB”) which the Company is investigating more extensively, leading to Lexaria’s patent application titled: “Enhancement of Delivery of Lipophilic Active Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders.”
It is well documented that nicotine – while addictive – does not cause cancer. It is the tar and other chemicals formed when cigarettes are combusted that cause cancer. Thus, an efficient delivery mechanism of minute quantities of nicotine that does not require combustion could lead to greatly reduced death and disease through the avoidance of smoking, while also potentially aiding reduced chemical dependence on nicotine until such time as addictive-avoidance behaviours can be empowered.
Lexaria’s surprising discovery of the DehydraTECHTM apparent effectiveness in crossing the BBB also opens the door to possibilities of delivering other therapeutic drugs in the treatment of intractable diseases.
The BBB, while providing effective protection to the brain against circulating toxins, also creates major difficulties in the pharmacological treatment of brain diseases. Most charged molecules, and most molecules over 700 Daltons in size, are unable to pass through the barrier, and smaller molecules may be conjugated in the liver. These factors create major difficulties in the pharmacological treatment of diseases of the brain and central nervous system (“CNS”), such as Alzheimer’s disease, Parkinson’s disease, bacterial and viral infections and cancer.
Many therapeutic agents for the treatment of diseases and disorders of the brain and CNS are sufficiently hydrophilic to preclude direct transport across the BBB. Furthermore, these drugs and agents are susceptible to degradation in the blood and peripheral tissues that increase the dose necessary to achieve a therapeutically effective serum concentration. However, as described above, although lipophilicity is generally associated with molecules that are easily able to cross the blood-brain barrier, lipophilicity is not the leading characteristic for molecules that transverse the blood-brain barrier. Seelig and colleagues studied the association of different factors with the ability of molecules to diffuse across the blood-brain barrier, including lipophilicity, Gibbs Adsorption Isotherm, a Co CMC Plot, and the surface area of the drug to water and air (Seelig et al. (1994) Proc. Nat. Acad. Sci. (USA) 91:68-72). Their results showed that barrier permittivity is based on a complex interaction between relative size and the surface activity of the molecule, in which the surface activity includes the molecular properties of both hydrophobic and charged residues (Seelig et al. (1994) Proc. Nat. Acad. Sci. (USA) 91:68-72).
Prior methods for delivering drugs across the BBB involve three general categories: (1) liposome-based methods, where the therapeutic agent is encapsulated within the carrier; (2) synthetic polymer-based methods, where particles are created using synthetic polymers to achieve precisely-defined size characteristics; and (3) direct conjugation of a carrier to a drug, where the therapeutic agent is covalently bound to a carrier such as insulin. Liposomes are attractive for transporting drugs across the BBB because of their large carrying capacity. However, liposomes are generally too large to effectively cross the BBB, are inherently unstable, and their constituent lipids are gradually lost by absorption by lipid-binding proteins in the plasma. Synthetic polymers have run into difficulties having the drug carried across the cell only to be trapped in an endothelial cell or a lysosome, instead of the desired result of being ejected into the brain parenchyma.
Direct conjugation of pharmacological agents with the substances that can be transported across the BBB, such as insulin, has also been attempted. Insulin and insulin-like growth factors are known to cross the blood brain barrier by specialized facilitated diffusion systems. (Reinhardt et al. (1994) Endocrinology 135(5): 1753-1761). Specific transporters also exist for glucose and for large amino acids such as tryptophan. However, the specificity of the insulin transporter has proved to be too high to allow pharmacological agents covalently linked to insulin to cross into the brain. Similar results have been obtained with glucose and amino acid conjugates, whose uptake has been observed to obey the same general principles as other low-molecular weight substances, with only uncharged molecules below 700 Da achieving significant access to the brain.
Lexaria’s application requests patent protection for the delivery of cannabinoids, terpenes and terpenoids, non-steroidal anti-inflammatory drugs (i.e., NSAIDs), vitamins, nicotine, phosphodiesterase type 5 (PDE5) inhibitors, estrogen, progestin, testosterone, scopolamine and more, utilizing Lexaria’s already-patented DehydraTECHTM methodology combined with any of a wide variety of emulsifiers, starches, oils, flavorings and foods.
With approximately 50 patents now granted or pending worldwide, the Company’s policy has evolved to continue to issue news releases on material patent filings and issuances, but not on every patent-related development.
Dr. Ed Ergenzinger was also Director of Intellectual Property and Legal Affairs, Duke Human Vaccine Institute, at Duke University. This is where Dr. Matthew Fraser is associate professor and director of basic science research in the department of surgery, division of urology.
So all 4 of these experts who have been appointed to Lexaria's advisory board have been recruited from institutions where Dr. Ergenzinger has worked.
He obviously knows them personally and has shown them the results of Lexaria's research and they're intrigued and want to be involved.
I haven't bought any shares for a long time, but I'm buying more today!
Well, maybe 1906 is the private company that has licensed DehydraTech for beverages? I believe they were only licensed for edibles before.
That's great, growing revenue for Lexaria. Also shows that 1906's product is well liked and that DehydraTech works.
Dr. Ed Edergenzinger is an adjunct professor of law at Wake Forest University
https://www.linkedin.com/in/edergenzinger
Also, the National Research Council of Canada, our research partner, has extensive experience in investigating methods of crossing the blood-brain barrier.
Interesting that every one of them has a strong background in neuroscience and of course Chief Legal Officer and Senior Vice President of Innovation
Dr. Ergenzinger also has a strong background in that field and also vaccines. In order to be an effective drug to treat neurological disorders, the drug would have to be able to cross the blood-brain barrier, that has been the challenge to date.